天津医药 ›› 2022, Vol. 50 ›› Issue (12): 1254-1258.doi: 10.11958/20220316

• 细胞与分子生物学 • 上一篇    下一篇

lncRNA SOX21-AS1的表达对卵巢癌细胞增殖和转移能力的影响及机制研究

陈霄(), 吴小颖, 安明   

  1. 四川大学华西三亚医院妇产科(邮编572000)
  • 收稿日期:2022-02-28 修回日期:2022-06-01 出版日期:2022-12-15 发布日期:2022-12-30
  • 作者简介:陈霄(1987),女,主治医师,主要从事妇产科疾病相关方面研究。E-mail:chenxiao19870352@163.com

Effects of lncRNA SOX21-AS1 expression on proliferation and metastasis of ovarian cancer cells and its mechanism

CHEN Xiao(), WU Xiaoying, AN Ming   

  1. Department of Obstetrics and Gynecology, West China Sanya Hospital, Sichuan University, Sanya 572000, China
  • Received:2022-02-28 Revised:2022-06-01 Published:2022-12-15 Online:2022-12-30

摘要:

目的 探讨长链非编码RNA SRY-box转录因子21反义RNA 1(lncRNA SOX21-AS1)对卵巢癌细胞增殖和转移能力的影响及其作用机制。方法 选取卵巢癌组织和其邻近的癌旁组织各75例,另选取卵巢癌细胞株SKOV3、A2780、OVCR3和人卵巢正常上皮细胞HOSE作为实验对象,实时荧光定量PCR法检测lncRNA SOX21-AS1在组织和细胞中的表达。根据是否干扰lncRNA SOX21-AS1表达将细胞分为si-NC组和si-SOX21-AS1组。MTS实验和平板克隆实验检测细胞增殖能力,Transwell实验检测细胞转移能力,TOP/FOP荧光素酶实验和Western blot实验检测细胞中Wnt/β-catenin信号通路活性和相关蛋白表达水平。结果 与癌旁组织相比,lncRNA SOX21-AS1在卵巢癌组织中的表达上调(P<0.05)。与卵巢正常上皮细胞HOSE相比,lncRNA SOX21-AS1在卵巢癌细胞中的表达上调,SKOV3中最高(P<0.05)。与FIGO分期Ⅰ-Ⅱ期、无淋巴结转移的患者相比,FIGO分期Ⅲ-Ⅳ期、有淋巴结转移患者lncRNA SOX21-AS1相对表达水平升高(P<0.05)。干扰lncRNA SOX21-AS1表达可抑制卵巢癌细胞增殖和转移能力、抑制Wnt/β-catenin信号通路活性并降低Wnt/β-catenin信号通路各蛋白的表达水平(P<0.05)。结论 lncRNA SOX21-AS1在卵巢癌组织和细胞中高表达,干扰lncRNA SOX21-AS1的表达可抑制卵巢癌细胞增殖和转移能力。

关键词: 卵巢肿瘤, 细胞增殖, 肿瘤转移, 基因表达调控,肿瘤, 长链非编码RNA SRY-box转录因子21反义RNA 1

Abstract:

Objective To study the effect of long non-coding RNA SRY-box transcription factor 21 antisense RNA 1 (lncRNA SOX21-AS1) on the proliferation and metastasis of ovarian cancer cells and its mechanism. Methods A total of 75 samples of ovarian cancer and 75 samples of adjacent paracancerous tissues were selected. Ovarian cancer cell lines SKOV3, A2780, OVCR3 and human normal ovarian epithelial cells HOSE were selected as the experimental objects. The expression levels of lncRNA SOX21-AS1 in tissues and cells were detected by qPCR. The cells were divided into the si-NC group and the si-SOX21-AS1 group according to whether they interfered with the expression of lncRNA SOX21-AS1. MTS assay and plate cloning assay were used to detect cell proliferation ability, and Transwell assay was used to detect cell transfer ability. TOP/FOP luciferase assay and Western blot assay were used to detect Wnt/β-catenin signaling pathway activity and related protein expression levels in cells. Results Compared with adjacent tissues, the expression of lncRNA SOX21-AS1 was significantly up-regulated in ovarian cancer tissues (P<0.05). Compared with normal ovarian epithelial cells HOSE, the expression of lncRNA SOX21-AS1 was significantly up-regulated in ovarian cancer cells (P<0.05). Compared with patients with FIGO stage I-II and patients with no lymph node metastasis, the relative expression level of lncRNA SOX21-AS1 was significantly higher in patients with FIGO stage III-IV and patients with lymph node metastasis (P<0.05). Interfering with the expression of lncRNA SOX21-AS1 significantly inhibited cell proliferation and metastasis, Wnt/β-catenin signaling pathway activity and Wnt/β-catenin signaling pathway related protein expression (P<0.05). Conclusion lncRNA SOX21-AS1 is highly expressed in ovarian cancer tissues and cells. Interfering with the expression of lncRNA SOX21-AS1 significantly inhibits the proliferation and metastasis of ovarian cancer cells.

Key words: ovarian neoplasms, cell proliferation, neoplasm metastasis, gene expression regulation, neoplastic, lncRNA SOX21-AS1

中图分类号: